Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection

Hepatology International - Tập 9 Số 2 - Trang 231-242 - 2015
Ching‐Sheng Hsu1,2, Wei Liang Liu3, You‐Chen Chao1,2, Hans Hsienhong Lin1,2, Tai‐Chung Tseng1,2, Chia-Chi Wang1,2, Ding–Shinn Chen4,5,3, Jia‐Horng Kao4,3
1Division of Gastroenterology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan
2School of Medicine, Tzu Chi University, Hualien, Taiwan
3Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
4Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
5Genomics Research Center, Academia Sinica, Nankang, Taiwan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–2023

Hsu CS, Liu CH, Liu CJ, Hsu SJ, Chen CL, Hwang JJ, Lai MY, et al. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J Gastroenterol Hepatol 2010;25:970–977

Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan HY, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39:883–893

Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820–1832

Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111–121

Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111–117

Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97:1688–1694

Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168–1172

Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9:5699–5704

Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case–control study in Greece. J Clin Endocrinol Metab 2003;88:993–997

Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, Lu SN, et al. Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan. Cancer Epidemiol Biomarkers Prev 2014;23:1659–1671

Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer 2011;129:2226–2235

Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957–969

Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009;29:1431–1438

Khattab MA, Eslam M, Aly MM, Shatat M, Hussen A, Moussa YI, Elsaghir G, et al. Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4. J Clin Gastroenterol 2012;46:871–879

Hui CK, Zhang HY, Lee NP, Chan W, Yueng YH, Leung KW, Lu L, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 2007;47:191–202

Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, Chu ES, et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2010;105:132–138

Kukla M, Ciupinska-Kajor M, Kajor M, Wylezol M, Zwirska-Korczala K, Hartleb M, Berdowska A, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2012;61:147–153

Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007;133:1458–1465

Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003;38:153–157

Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993;21:303–308

Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, Kao JH, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006;26:1087–1094

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645

Cordero A, Andres E, Ordonez B, Leon M, Laclaustra M, Grima A, Luengo E, et al. Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol 2009;104:1393–1397

Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328:983

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059–1062

Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2013;141:517–525, 525 e511–e512

Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, Liu CJ, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2013;15:1133–1139

Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659–666

Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–293

Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015;61:292–302

Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat 2013;20:e3–e10

Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726–736

Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202–1219

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–769

Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010;12:365–383

Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res 2001;50:443–459

Manolakopoulos S, Bethanis S, Liapi C, Stripeli F, Sklavos P, Margeli A, Christidou A, et al. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol 2007;7:17

Kukla M, Mazur W, Buldak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines–visfatin, chemerin and vaspin—in chronic hepatitis. Mol Med 2011;17:1397–1410

Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, Karslioglu Y, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 2013;12:548–555

Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008;15:91–101

Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int 2011;31:282–290

Hajjou M, Norel R, Carver R, Marion P, Cullen J, Rogler LE, Rogler CE. cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J Med Virol 2005;77:57–65

Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat 2012;19:e48–e57

Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, Tsai KS, et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011;32:876–881

Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012;7:e34198

Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, Chen DS. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int 2009;3:364–370

Yoon S, Jung J, Kim T, Park S, Chwae YJ, Shin HJ, Kim K. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor gamma, controls hepatitis B virus replication. Virology 2011;409:290–298

Yokoyama H, Hirose H, Ohgo H, Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 2004;41:19–24

Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734–2741

Shimizu I, Kohno N, Tamaki K, Shono M, Huang HW, He JH, Yao DF. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007;13:4295–4305

Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case–control study among men. J Natl Cancer Inst 2001;93:1644–1651

Wu D, Li H, Xiang G, Zhang L, Li L, Cao Y, Zhang J. Adiponectin and its receptors in chronic hepatitis B patients with steatosis in china. Hepat Mon 2013;13:e6065

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49:1017–1044

Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004;287:E82–E89